Cancer Cell-Sticky Hydrogels to Target the Cell Membrane of Invading Glioblastomas
Source abstract
Abstract
Owing to their remarkable infiltrative traits, glioblastomas develop unclear tumor margins toward the brain, hampering the complete resection. Since the remaining invasive cells tend to have resistance to therapeutics and cause recurrence around the surgical voids, this has been a major challenge for glioblastoma treatment. Thus, we design a cancer cell-sticky hydrogel (CSH) that interacts with the glioblastoma cells to impede their invasive motility by modifying the cell membrane with active thiol-enriched interfaces. Highly reactive thiols at the cell surface can make the infiltrated cancer cells adhere to the hydrogel, resulting in increased cell adhesion and decreased motility. Cotreatment with the CSH and chemical inhibitors of the major proinvasive molecules, focal adhesion kinase and hyaluronic acid synthase, maximized the invasion-inhibitory effect. In addition, a significant decrease in tumor mass was achieved via CSH implantation in mouse models. Overall, our results highlight the use of the CSH to inhibit the aggressive invasion as a novel therapeutic strategy against glioblastoma.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Immune cells in cancer · Cancer, Hypoxia, and Metabolism
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Bio and Brain Engineering, KAIST, Daejeon 34141, Korea
KAIST Institute for Health Science and Technology, Daejeon 34141, Korea
Department of Bioengineering, University of California, Berkeley, California 94720, United States
Funding
Korea Health Industry Development Institute · National Research Foundation of Korea · KAIST
References (25)
Show source-provided references
1. 10.1038/ncb0402-e8310.1038/ncb0402-e83 ↗
2. 10.1038/nrm390410.1038/nrm3904 ↗
3. 10.1038/onc.2011.2710.1038/onc.2011.27 ↗
4. 10.1038/nrclinonc.2017.9510.1038/nrclinonc.2017.95 ↗
5. 10.1016/j.ccell.2017.02.00910.1016/j.ccell.2017.02.009 ↗
6. 10.1038/sigtrans.2017.4010.1038/sigtrans.2017.40 ↗
7. 10.1016/j.cell.2011.02.01310.1016/j.cell.2011.02.013 ↗
8. 10.1038/nrc281810.1038/nrc2818 ↗
9. 10.1016/j.biocel.2004.01.01310.1016/j.biocel.2004.01.013 ↗
10. 10.1001/jama.2013.28031910.1001/jama.2013.280319 ↗
11. 10.1056/nejmoa04333010.1056/nejmoa043330 ↗
12. 10.1038/nrd141410.1038/nrd1414 ↗
13. 10.1038/nrd138010.1038/nrd1380 ↗
14. 10.3171/jns.1991.74.3.044110.3171/jns.1991.74.3.0441 ↗
15. 10.3747/co.2007.14710.3747/co.2007.147 ↗
16. 10.1602/neurorx.2.1.310.1602/neurorx.2.1.3 ↗
17. 10.1016/j.jconrel.2016.05.04410.1016/j.jconrel.2016.05.044 ↗
18. 10.1021/acsami.8b1256610.1021/acsami.8b12566 ↗
19. 10.1007/BF0248344910.1007/BF02483449 ↗
20. 10.1016/j.biomaterials.2010.06.06110.1016/j.biomaterials.2010.06.061 ↗
21. 10.1038/srep2491210.1038/srep24912 ↗
22. 10.1002/adhm.20140038410.1002/adhm.201400384 ↗
23. 10.1158/1535-7163.MCT-12-070110.1158/1535-7163.MCT-12-0701 ↗
24. 10.1158/1541-7786.MCR-13-062910.1158/1541-7786.MCR-13-0629 ↗
25. 10.1021/bm025744e10.1021/bm025744e ↗